Disc Medicine Quarterly Income Statement
NASDAQ: IRONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
62.06+1.29 (+2.12%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Disc Medicine revenue and earnings
Disc Medicine reported a net loss of $59.5 million, compared with a loss of $55.2 million a year earlier. Diluted earnings per share came in at -$1.54.
Summary generated from market data by MetaCap's automated system. Methodology
Disc Medicine income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 65.08M | 69.52M | 66.97M | 67.70M | 61.41M | 39.95M | 34.55M | 32.86M | 30.85M | 31.46M | 29.71M | 18.96M |
| Research & Development | 46.93M | 45.90M | 46.22M | 50.33M | 46.32M | 27.76M | 24.80M | 24.68M | 23.48M | 23.70M | 22.57M | 14.42M |
| Selling, General & Admin | 18.14M | 23.62M | 20.75M | 17.36M | 15.09M | 12.18M | 9.75M | 8.17M | 7.37M | 7.76M | — | — |
| Operating Income | -65.08M | -69.52M | -66.97M | -67.70M | -61.41M | -39.95M | -34.55M | -32.86M | -30.85M | -31.46M | -29.71M | -18.96M |
| Interest Expense | 908.00K | 844.00K | 883.00K | 917.00K | 910.00K | 897.00K | 572.00K | 0 | 0 | 0 | — | — |
| Other Income (Expense) | 5.61M | 6.07M | 6.53M | 5.48M | 6.21M | 5.98M | 5.27M | 6.37M | 4.56M | 4.52M | 6.17M | 4.86M |
| Pretax Income | -59.46M | -63.45M | -60.44M | -62.22M | -55.20M | -33.97M | -29.28M | -26.48M | -26.29M | -26.94M | -23.55M | -14.10M |
| Income Tax | 69.00K | 51.00K | 88.00K | 102.00K | 52.00K | 119.00K | 176.00K | 114.00K | 60.00K | 5.00K | 32.00K | 20.00K |
| Net Income | -59.53M | -63.50M | -60.53M | -62.32M | -55.25M | -34.09M | -29.46M | -26.60M | -26.35M | -26.95M | -23.58M | -14.12M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.54 | -1.65 | -1.64 | -1.77 | -1.58 | -1.02 | -0.95 | -0.89 | -1.03 | -1.09 | -0.90 | -0.58 |
| EPS (Diluted) | -1.54 | -1.65 | -1.64 | -1.77 | -1.58 | -1.02 | -0.95 | -0.89 | -1.03 | -1.09 | -0.90 | -0.58 |
| Shares Outstanding (Basic) | 38.69M | 38.49M | — | 35.18M | 35.02M | 33.32M | — | 29.94M | 25.65M | 24.81M | — | 24.32M |
| Shares Outstanding (Diluted) | 38.69M | 38.49M | — | 35.18M | 35.02M | 33.32M | — | 29.94M | 25.65M | 24.81M | — | 24.32M |
| EBITDA | -64.98M | -69.44M | -66.88M | -67.61M | -61.33M | -39.93M | -34.54M | -32.84M | -30.74M | -31.44M | -29.69M | -18.93M |
This table shows 12 quarterly periods of Disc Medicine's income statement, from Q2 2026 back to Q3 2023, across 14 line items including operating expenses, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow IRON's reporting calendar. What is a income statement?